Ophthalmology Therapeutics: Does current pipeline innovation hold the potential to affect the future ophthalmology market?

This Frontier Pharma: Ophthalmology Therapeutics assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products.

Pune, India - March 14, 2018 /MarketersMedia/ —

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs

Reasons To Buy
• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
• Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
• Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
• Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Get this report at: https://www.themarketreports.com/report/buy-now/935550

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935550

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/ophthalmology-therapeutics-does-current-pipeline-innovation-hold-the-potential-to-affect-the-future-ophthalmology-market/314326

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs%20%20

Source: MarketersMedia

Release ID: 314326

Latest News

Global shares edge up, China pulls Asia down, oil subdued pre: OPEC

Jun 21, 2018

By Wayne ColeSYDNEY (Reuters) - Shares crept higher in most major markets on Thursday as a lull in the Sino-U.S. trade tussle and talk of more stimulus in China helped calm nerves, though the nagging trade tensions caused Chinese shares to slip, dragging other Asian markets lower.Oil prices eased a touch as nerves grew ahead of Friday's meeting between OPEC and other big producers, including Russia, with growing expectations that the Vienna talks could result in an agreement to increase crude supplies. [O/R]European shares are expected to rise, with spread-betters calling a higher opening of 0.4 percent in Britain's FTSE...

European autos sink on Daimler tariff hit while markets wilt

Jun 21, 2018

By Helen ReidLONDON (Reuters) - Autos stocks slammed the brakes on a relief bounce in European shares on Thursday, sinking after German carmaker Daimler warned profit would be hit by higher tariffs.The autos sector fell 2.3 percent to a nine-month low while the pan-European STOXX 600 eased down 0.2 percent as no new salvos were exchanged in an ongoing U.S.-China trade spat.Equity markets have been relatively resilient in the face of mounting trade concerns but fell broadly this week as U.S. President Donald Trump threatened additional tariffs on $200 billion worth of Chinese goods.Daimler became one of the biggest global...

May faces down pro-EU rebel lawmakers to win Brexit vote

Jun 21, 2018

By Elizabeth Piper and William JamesLONDON (Reuters) - Prime Minister Theresa May won a crucial Brexit vote in parliament on Wednesday, keeping her divided government's plans to end more than 40 years of British partnership with the European Union on track.After pro-EU Conservative lawmaker Dominic Grieve said he would support the government's proposal for a "meaningful vote" in parliament on Britain's exit, a potential rebellion that could have undermined May's authority was averted.May adopted a high-risk strategy by facing off with rebels in her Conservative Party, and it paid off. The upper house of parliament later approved the bill, paving...

Exclusive: Pope criticizes Trump administration policy on migrant family separation

Jun 21, 2018

By Philip PullellaVATICAN CITY (Reuters) - Pope Francis has criticized the Trump administration's policy of separating migrant families at the Mexican border, saying populism is not the answer to the world's immigration problems.Speaking to Reuters, the Pope said he supported recent statements by U.S. Catholic bishops who called the separation of children from their parents "contrary to our Catholic values" and "immoral"."It's not easy, but populism is not the solution," Francis said on Sunday night.In a rare, wide-ranging interview, the pope said he was optimistic about talks that may lead to a historic agreement over the appointment of bishops in...

Exclusive: Pope says China talks going well, dialogue worth the risk

Jun 21, 2018

By Philip PullellaVATICAN CITY (Reuters) - Pope Francis has voiced optimism for improved ties between the Vatican and China, rejecting criticism that the Holy See may be selling out Catholics to Beijing's communist government.The Vatican and China are in advanced talks to resolve a dispute over the appointment of bishops in China, one of the biggest obstacles to resuming diplomatic ties that were cut almost 70 years ago."We are at a good point," the pope told Reuters in an interview at his Vatican residence.China's estimated 12 million Catholics are split between an underground Church that swears loyalty to the Vatican...

Search

Obserworld delivers the most accurate and up-to-date world news for the global audience with a thorough research and in-depth interviews. Discover the world through Obserworld.

Contact us: sales[at]obserworld.com